NicOx announced the terms of its rights issue to advance the lead product naproxcinod, for treating osteoarthritis, and its broader portfolio broader, fixing the new shares at Euros 14.20 each.
The company is offering 9,131,526 new ordinary shares and expects to raise approximately Euros130 million. The new shares will represent 24 percent of the equity.
Receive our Policy Bulletin each Tuesday & Thursday and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
